公司資料
Citius Pharma 股價、新聞與催化劑
- 股票代碼:
- CTXR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.54 USD (+1.73%)
收盤價
最後更新: 2026年10月1日
16.6M USD
市值
股價為何變動
截至 2026年10月1日，CTXR 上漲 1.73%，收於 $0.5402。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Critical-Care and Oncology Portfolio
Citius Pharmaceuticals develops and commercializes products for oncology, infectious disease, and other critical-care settings. The business includes a majority interest in publicly traded Citius Oncology together with wholly owned late-stage programs.
LYMPHIR in Cutaneous T-Cell Lymphoma
LYMPHIR is an FDA-approved targeted fusion protein for adults with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. Commercialization is conducted through Citius Oncology, giving the broader group an approved oncology franchise.
Mino-Lok Catheter Salvage Therapy
Mino-Lok is an antibiotic lock solution designed to treat catheter-related bloodstream infections while preserving the indwelling central venous catheter. The product combines antimicrobial and anti-biofilm components and completed a Phase 3 study that met its primary and secondary endpoints.
Halo-Lido for Hemorrhoids
Halo-Lido is a topical formulation combining halobetasol and lidocaine for symptomatic treatment of hemorrhoids. The candidate has completed a Phase 2b study, and the company is evaluating the regulatory path for further development.
Lifecycle and Combination Development
Investigator-sponsored studies are exploring LYMPHIR in sequences or combinations with other cancer treatments, including checkpoint inhibitors and CAR-T therapy. These programs may extend the clinical role of the approved product beyond its initial label.
Portfolio-Based Structure
Citius uses separate subsidiaries and strategic transactions to finance and commercialize individual assets. This structure allows the company to retain economic exposure to LYMPHIR while independently advancing Mino-Lok and Halo-Lido.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。